LNK01004 / Lynk Pharmaceuticals - LARVOL DELTA

Lynk Pharmaceuticals Announces Key Phase II Clinical Results of LNK01004 for the Treatment of Patients with Moderate-to-Severe Atopic Dermatitis (PRNewswire-Asia) - "A total of 75 patients were enrolled....Efficacy results demonstrated that after 8 weeks of treatment, both LNK01004 dose groups achieved higher EASI-75 response rates than the vehicle group, with more pronounced benefits in patients with higher baseline BSA. Among patients with BSA ≥10%, the EASI-75 response rates for the 0.3%, 1.0%, and vehicle groups were 61.1%, 46.2%, and 20% respectively. The vIGA-AD (score 0/1 with ≥2-point improvement) response rates were 44.4%, 38.5%, and 10%, respectively. In patients with BSA ≥20%, both LNK01004 groups showed even greater clinical improvements..."

P2 data • Atopic Dermatitis

A Study to Evaluate the Efficacy and Safety of LNK01004 Ointment in Adults With Atopic Dermatitis (clinicaltrials.gov) - P2 | N=75 | Active, not recruiting | Sponsor: Lynk Pharmaceuticals Co., Ltd

New P2 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Lynk Pharmaceuticals Announces Positive Results from Phase 1b Clinical Study of LNK01004 for the Treatment of Atopic Dermatitis (PRNewswire) - P1b | N=28 | NCT06553287 | Sponsor: Lynk Pharmaceuticals Co., Ltd | "Lynk Pharmaceuticals...announced positive results from its Phase 1b clinical study of LNK01004...for the treatment of atopic dermatitis....The trial results showed that LNK01004 ointment demonstrated good safety and tolerability for up to 4 weeks of topical application; no measurable skin irritation was observed, and no patient withdrew from the study. Among the results, the 1.0% dose group of LNK01004 showed the most positive efficacy outcomes, with EASI-75, IGA 0/1, and PP-NRS4 response rates of 63%, 50%, and 75%, respectively, after 4 weeks of treatment (compared to 17%, 17%, and 33%, respectively, in the placebo group). The positive results from this study provide a solid foundation for the smooth progression of subsequent clinical trials."

P1 data • Atopic Dermatitis

Safety, Tolerability and Pharmacokinetics of LNK01004 Ointment in Adults With Atopic Dermatitis. (clinicaltrials.gov) - P1 | N=28 | Completed | Sponsor: Lynk Pharmaceuticals Co., Ltd

New P1 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Lynk Pharmaceuticals Announces First Atopic Dermatitis Patient Dosed with LNK01004 in Phase Ib Clinical Study (PRNewswire-Asia) - "Lynk Pharmaceuticals...announced that it has dosed the first patient with atopic dermatitis in a Phase Ib clinical trial of its innovative drug LNK01004. The trial was designed to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of LNK01004 ointment in Chinese patients with mild to moderate atopic dermatitis."

Trial status • Atopic Dermatitis • Dermatitis • Immunology • Inflammation

Lynk Pharmaceuticals Announces First Cohort of Psoriatic Patients Dosed with LNK01004 in Phase Ib Clinical Study (PRNewswire-Asia) - "Lynk Pharmaceuticals...announced that it has dosed the first cohort of psoriatic patients in a Phase Ib clinical trial of its innovative drug LNK01004. The trial was designed to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of LNK01004 ointment in Chinese patients with mild to moderate plaque psoriasis."

Trial status • Immunology • Psoriasis

Lynk Pharmaceuticals Announces IND Approval of LNK01004 for Atopic Dermatitis in China (PRNewswire) - "Lynk Pharmaceuticals...announced that its innovative drug LNK01004, has been approved by National Medical Products Administration (NMPA) for clinical trials in the treatment of atopic dermatitis (AD)....Approval for the treatment of atopic dermatitis is the second clinical indication approved for LNK01004 in China."

Non-US regulatory • Atopic Dermatitis • Immunology